AN2 Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

ANTX$4.33+8.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Cash Flows

(in thousands)

	Nine Months EndedSeptember 30,
	2025	2024
Cash flows used in operating activities
Net loss	$(26,464)	$(43,799)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	4,846	6,558
Net accretion of discount on investments	(953)	(2,712)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	1,353	(8)
Accounts payable	(1,091)	(965)
Accrued compensation	68	(1,908)
Accrued liabilities	(1,749)	(1,760)
Other current liabilities	(608)	610
Net cash used in operating activities	(24,598)	(43,984)
Cash flows from investing activities
Purchases of investments	(37,863)	(22,371)
Maturities of investments	59,000	83,840
Net cash provided by investing activities	21,137	61,469
Cash flows from financing activities
Proceeds from issuance of common stock under the ESPP	86	147
Proceeds from exercise of stock options	27	225
Net cash provided by financing activities	113	372
Net (decrease) increase in cash and cash equivalents	(3,348)	17,857
Cash and cash equivalents at the beginning of the period	21,351	15,647
Cash and cash equivalents at the end of the period	$18,003	$33,504

AN2 Therapeutics, Inc.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.